C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter C—Drugs: GeneralPart 211—Current Good Manufacturing Practice for Finished PharmaceuticalsSubpart C—Buildings and Facilities

21 C.F.R. § 211.42 (2026)

Design and construction features

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1980–2014 5citing cases
At a glance

Courts have cited this section in 5 opinions since 1980.

(a) Any building or buildings used in the manufacture, processing, packing, or holding of a drug product shall be of suitable size, construction and location to facilitate cleaning, maintenance, and proper operations.

(b) Any such building shall have adequate space for the orderly placement of equipment and materials to prevent mixups between different components, drug product containers, closures, labeling, in-process materials, or drug products, and to prevent contamination. The flow of components, drug product containers, closures, labeling, in-process materials, and drug products through the building or buildings shall be designed to prevent contamination.

(c) Operations shall be performed within specifically defined areas of adequate size. There shall be separate or defined areas or such other control systems for the firm's operations as are necessary to prevent contamination or mixups during the course of the following procedures:

(1) Receipt, identification, storage, and withholding from use of components, drug product containers, closures, and labeling, pending the appropriate sampling, testing, or examination by the quality control unit before release for manufacturing or packaging;

(2) Holding rejected components, drug product containers, closures, and labeling before disposition;

(3) Storage of released components, drug product containers, closures, and labeling;

(4) Storage of in-process materials;

(5) Manufacturing and processing operations;

(6) Packaging and labeling operations;

(7) Quarantine storage before release of drug products;

(8) Storage of drug products after release;

(9) Control and laboratory operations;

(10) Aseptic processing, which includes as appropriate:

(i) Floors, walls, and ceilings of smooth, hard surfaces that are easily cleanable;

(ii) Temperature and humidity controls;

(iii) An air supply filtered through high-efficiency particulate air filters under positive pressure, regardless of whether flow is laminar or nonlaminar;

(iv) A system for monitoring environmental conditions;

(v) A system for cleaning and disinfecting the room and equipment to produce aseptic conditions;

(vi) A system for maintaining any equipment used to control the aseptic conditions.

(d) Operations relating to the manufacture, processing, and packing of penicillin shall be performed in facilities separate from those used for other drug products for human use.

[43 FR 45077, Sept. 29, 1978, as amended at 60 FR 4091, Jan. 20, 1995]
The 5 cases that cite 21 C.F.R. § 211.42 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENUS ex rel. Barry Rostholder v. Omnicare, Inc., 745 F.3d 694 (4th Cir. 2014).
cites § 211.42 1×cited by 55 cases
Where it cites § 211.42
“21 C.F.R. §§ 211.42 , 211.46(d). The regulations require that non-penicillin drugs be tested for the presence of penicillin “[i]f a reasonable possibility exists” that the non-penicillin drug has been exposed to penicillin cross-contamination.”
The case’s holding
A False Claims Act claim requires a relator to plausibly allege a false statement or fraudulent course of conduct, requisite scienter, materiality, and causation of government payment.
Later courts cite it for
“to plead an fca claim, a relator must plausibly allege four distinct elements: (1) there was a false statement or fraudulent course of conduct; (2) made or carried out with the requisite scienter knowledge; (3) that was material; and (4) that caused the government to pay out money or to forfeit moneys due (i.e., that involved a 'claim')(emphasis added).” · 6 citing courts
cites § 211.42 1×cited by 28 cases
Where it cites § 211.42
“at 7315; see also 21 C.F.R. § 211.42 (d) (“Operations relating to the manufacture, processing, and packing of penicillin shall be performed in facilities separate from those used for other drug products for human use.”
Later courts cite it for
“apply with equal force in the context of administrative judgment.” · 3 citing courts
3
GREENUnited States v. Richlyn Labs., Inc., 827 F. Supp. 1145 (E.D. Pa. 1992).
cites § 211.42 1×cited by 12 cases
Where it cites § 211.42
“” 21 C.F.R. § 211.42 . Adequate ventilation is to be provided and air filtration systems are to be used when appropriate on air supplies to production areas.”
Later courts cite it for
“indeed, because congress has seen fit to act in a given area by enacting a statute, irreparable injury must be presumed in a statutory enforcement action.” · 2 citing courts
4
GREENUnited States v. W. Serum Co., 498 F. Supp. 863 (D. Ariz. 1980).
cites § 211.42 1×cited by 7 cases
Later courts cite it for
“probable cause to believe that the drug in question was a new drug.” · 2 citing courts
5
GREENUnited States v. Richlyn Labs., Inc., 822 F. Supp. 268 (E.D. Pa. 1993).
cites § 211.42 1×cited by 6 cases
Where it cites § 211.42
“” 21 C.F.R. § 211.42 . Adequate ventilation is to be provided and air filtration systems are to be used when appropriate on air supplies to production areas.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
198019972014

One bar per year. Tallest: 1 case in 1980. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
E.D. Pa.2D. Ariz.14th Cir.1D.C. Cir.1
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com